SCHEMBL15570922

SCHEMBL15570922

CN1Cc2cc(-c3ccc(I)s3)ccc2C1=O

nearest known ligand 0.56

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
PRF1 P14222 20/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15571461 0.89 PRF1 (0.56) PRF1
SCHEMBL15571390 0.86 PRF1 (0.58) PRF1
SCHEMBL20924158 0.84 PRF1 (0.57) PRF1
SCHEMBL2015843 0.82 PRF1 (0.64) PRF1
SCHEMBL15571866 0.81 PRF1 (0.59) PRF1
SCHEMBL15571500 0.80 PRF1 (0.56) PRF1
SCHEMBL15571765 0.79 PRF1 (0.60) PRF1
SCHEMBL15571449 0.79 PRF1 (0.61) PRF1
SCHEMBL15570769 0.78 PRF1 (0.58) PRF1
SCHEMBL15571890 0.78 PRF1 (0.57) PRF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2888251-B1 PERFORIN INHIBITING BENZENESULFONAMIDE COMPOUNDS, PREPARATION AND USES THEREOF PETER MACCALLUM CANCER INST (AU) 2019-04-24 EP disclosed
EP-2888251-B1 PERFORIN INHIBITING BENZENESULFONAMIDE COMPOUNDS, PREPARATION AND USES THEREOF PETER MACCALLUM CANCER INST (AU) 2019-04-24 EP disclosed
US-9896443-B2 Perforin inhibiting benzenesulfonamide compounds, preparation and uses thereof PETER MACCALLUM CANCER INSTITUTE (AU) 2018-02-20 US disclosed
US-9896443-B2 Perforin inhibiting benzenesulfonamide compounds, preparation and uses thereof PETER MACCALLUM CANCER INSTITUTE (AU) 2018-02-20 US disclosed
US-20150218150-A1 PERFORIN INHIBITING BENZENESULFONAMIDE COMPOUNDS, PREPARATION AND USES THEREOF PETER MACCALLUM CANCER INSTITUTE (AU) 2015-08-06 US disclosed
US-20150218150-A1 PERFORIN INHIBITING BENZENESULFONAMIDE COMPOUNDS, PREPARATION AND USES THEREOF PETER MACCALLUM CANCER INSTITUTE (AU) 2015-08-06 US disclosed
US-20150218150-A1 PERFORIN INHIBITING BENZENESULFONAMIDE COMPOUNDS, PREPARATION AND USES THEREOF PETER MACCALLUM CANCER INSTITUTE (AU) 2015-08-06 US disclosed
EP-2888251-A1 PERFORIN INHIBITING BENZENESULFONAMIDE COMPOUNDS, PREPARATION AND USES THEREOF Peter MacCallum Cancer Institute (AU) 2015-07-01 EP disclosed
WO-2014028968-A1 PERFORIN INHIBITING BENZENESULFONAMIDE COMPOUNDS, PREPARATION AND USES THEREOF PETER MACCALLUM CANCER INSTITUTE (AU) 2014-02-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150218150-A1 PERFORIN INHIBITING BENZENESULFONAMIDE COMPOUNDS, PREPARATION AND USES THEREOF PRF1, GZMB, BAK1 PRF1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.